Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a current market capitalization of $82.23 million, announced today that it has been granted a new patent by the United States Patent and Trademark Office (USPTO). The patent, U.S. Patent No. 12,275,684, relates to enteric oral formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), and methods for treating hormone-dependent breast and reproductive tract disorders.
The patent aims to strengthen Atossa’s intellectual property portfolio around its proprietary (Z)-endoxifen formulations, which are being developed as a targeted therapy for hormone receptor-positive breast cancer. According to Steven Quay, M.D., Ph.D., President and CEO of Atossa, the patent issuance is a significant milestone in the company’s mission to advance treatments for breast cancer and underscores their dedication to providing effective therapeutic options to patients. While the company holds more cash than debt and maintains a strong current ratio of 14.99, it is currently burning through cash rapidly - a crucial factor for investors to monitor.
(Z)-endoxifen is considered one of the most potent SERMs for estrogen receptor inhibition and may degrade estrogen receptors. It has shown efficacy in patients resistant to other hormonal treatments and targets PKCβ1, an oncogenic protein, at clinically attainable blood concentrations. Atossa’s oral formulation of (Z)-endoxifen is designed to bypass the stomach to prevent conversion to the inactive (E)-endoxifen, and it has been well tolerated in clinical studies.
Atossa’s patent estate now includes multiple U.S. patents with over 100 claims related to (Z)-endoxifen formulations and their clinical applications. The company is currently studying (Z)-endoxifen for both the treatment and prevention of breast cancer, including a metastatic breast cancer program announced earlier this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.